Graft versus host disease can make everyday recovery after a stem cell or bone marrow transplant much harder. It happens when donor immune cells attack the body, and it most often affects the skin, gut, liver, eyes, or mouth. Many living with graft versus host disease may notice a rash, diarrhea, belly pain, dry eyes, mouth sores, or unusual tiredness, and early symptoms of graft versus host disease can be mild at first. It may start within the first 100 days after transplant or develop later, and not everyone will have the same experience. Graft versus host disease can sometimes be life-threatening, but treatment such as steroids, other immune-calming medicines, and supportive care often helps control it.
How many people live with Graft versus host disease?
Worldwide, there is no single direct count of how many people are living with graft-versus-host disease, because it is tracked as a complication after a donor stem cell or bone marrow transplant and the numbers vary depending on whether the short-term or long-term form is counted. Using recent transplant totals and widely used estimates that about 30% to 70% of people after a donor transplant may develop graft-versus-host disease, roughly 12,000 to 29,000 people worldwide each year (Worldwide Network for Blood and Marrow Transplantation, 2022; National Cancer Institute, 2024) and about 2,500 to 6,000 people in the United States each year (CIBMTR, 2023; National Cancer Institute, 2024) are estimated to be affected.
Overview
Graft versus host diseaseSymptoms
Graft versus host disease often causes a skin rash, diarrhea, belly pain, and nausea. Many living with graft versus host disease also have jaundice, dry eyes or mouth, and mouth sores. Early symptoms of graft versus host disease can feel like the flu.
Outlook and prognosis
The outlook for graft versus host disease varies with how severe it is and which organs are affected. Many people improve with prompt treatment, but ongoing skin, gut, liver, or lung problems can affect daily life and may need long-term follow-up.
Causes and risk factors
Graft versus host disease can develop after a stem cell or bone marrow transplant when donor immune cells attack the body. Risk rises with tissue-type mismatch, unrelated donors, older age, and stronger pretransplant treatment. Lifestyle factors usually are not causes.
Genetic influences
Genetics matter a lot in graft versus host disease, especially how closely donor and recipient tissue types match. Other gene differences in immune signaling can also affect risk, severity, and how someone responds to treatment.
Diagnosis
Graft versus host disease is diagnosed by reviewing symptoms, exam findings, and recent stem cell or bone marrow transplant history. Doctors often use blood tests, imaging, and sometimes a skin, liver, or gut biopsy to confirm graft versus host disease.
Treatment and drugs
Treatment for graft versus host disease aims to calm the donor immune cells that are attacking the body. Many people start steroid medicine, and some need other immune-lowering drugs. Skin, gut, eye, or liver symptoms are treated at the same time.
Symptoms
Graft-versus-host disease can affect the skin, gut, liver, eyes, mouth, lungs, and other parts of the body after a stem cell transplant. Some problems come on quickly, while others build more slowly over weeks or months. Symptoms vary from person to person and can change over time. Knowing the early symptoms of graft-versus-host disease can help people get care before eating, seeing, breathing, or everyday comfort become harder.
A red or darker-than-usual rash can spread over the face, hands, feet, chest, or back, and the skin may itch, burn, or feel sore. In chronic disease, skin can also become dry, tight, thickened, or less flexible, which may make moving around less comfortable.
Watery diarrhea, belly cramps, nausea, vomiting, and loss of appetite are common when graft-versus-host disease affects the digestive tract. Some people also notice bloating, trouble keeping food down, or unplanned weight loss.
Mouth soreness, dry mouth, or sensitivity to spicy, acidic, or rough foods can make meals difficult. Some may notice white patches, gum irritation, or pain with swallowing.
Dry, gritty, burning eyes are common, almost like there is sand in them. Light sensitivity, blurred vision, or trouble wearing contact lenses may follow.
How people usually first notice Graft versus host disease?
People usually first notice graft-versus-host disease when new symptoms appear after a stem cell or bone marrow transplant, often starting with a skin rash, diarrhea, belly pain, nausea, or yellowing of the eyes or skin. In the early days or weeks, acute graft-versus-host disease often shows up in the skin, gut, or liver, while later on, chronic graft-versus-host disease may be first noticed through dry eyes, mouth sores, skin tightening, cough, or joint stiffness. Because these symptoms can overlap with infections and medication side effects, it is important to tell your transplant team quickly if anything new appears, even if it seems mild at first.
Types of Graft versus host disease
Graft versus host disease can affect day-to-day life in different ways depending on when it starts and which body systems it involves. Doctors sometimes classify symptoms as acute versus chronic. Acute graft versus host disease often brings faster, more inflammatory symptoms, while chronic graft versus host disease can feel more long-lasting and scar-like, affecting movement, comfort, and routine activities. In practice, the main types of graft versus host disease are defined by these patterns, and some people have features of both.
Acute GVHD
Acute graft versus host disease usually develops in the first weeks to months after a stem cell transplant, although it can also appear later. It most often affects the skin, gut, and liver, causing a rash, diarrhea, belly pain, nausea, or abnormal liver blood tests. For many, early symptoms of graft versus host disease show up as a new widespread rash or sudden digestive problems.
Chronic GVHD
Chronic graft versus host disease tends to last longer and can involve many parts of the body, including the skin, mouth, eyes, lungs, joints, and genitals. Symptoms may include dry eyes, mouth sores, tight or thickened skin, joint stiffness, shortness of breath, or trouble swallowing. Symptoms don’t always look the same for everyone.
Overlap syndrome
Overlap syndrome means someone has signs of both acute and chronic graft versus host disease at the same time. This can look like an inflammatory rash or diarrhea together with longer-term problems such as dry eyes, mouth changes, or skin tightening. Having one pattern does not always rule out features of the other.
Can I slow down the onset of symptoms?
Usually, no: there is no good evidence that diet, exercise, supplements, or other lifestyle changes can meaningfully delay the start of graft-versus-host disease, because it is mainly caused by donor immune cells reacting after a donor stem cell or bone marrow transplant. What can lower the risk, though not fully prevent it, is careful donor matching and the preventive medicines your transplant team gives to calm the immune system before and after transplant, along with close follow-up. Staying in close touch with your team and reporting small changes like a new rash, diarrhea, dry eyes, or mouth sores may help problems be found and treated earlier, which can still make a real difference even if it cannot guarantee graft-versus-host disease will be avoided.
What genetics can tell you about symptoms
Genetics can give some clues about how graft-versus-host disease may show up, but they do not predict symptoms with certainty. The most important genetic factor is how closely the donor and recipient are matched in key immune system genes; poorer matching can raise the chance of graft-versus-host disease and may make it more severe or affect which organs, such as the skin, gut, or liver, become involved. Other immune-related genetic differences may also influence whether symptoms start earlier or later and how strong they are, but day-to-day symptoms still vary a lot from one person to another.
Causes and risk factors
After a stem cell transplant, graft versus host disease can bring problems like a rash, stomach upset, or dry eyes that affect daily life. It happens when immune cells from the donor see your body as foreign and attack healthy tissues. The main risk factors for graft versus host disease include a less-than-close tissue match, an unrelated donor, older age, and stem cells taken from the bloodstream instead of the bone marrow. On top of genetics, everyday habits also matter. Infections, stronger chemotherapy or radiation before transplant, smoking, and trouble taking anti-rejection medicine as prescribed may raise the chance of graft versus host disease or make it more severe.
What are the most common causes or risk factors?
The main cause of graft-versus-host disease is getting donor bone marrow or blood-forming stem cells whose immune cells see the recipient’s body as foreign and attack it. The risk is higher when the donor and recipient are not a close tissue match, which is largely based on inherited genes, and when the donor is unrelated or the person getting the transplant is older. It can also be more likely with certain donor-recipient sex combinations, especially a female donor for a male recipient, and after stronger transplant treatments such as high-dose chemotherapy or radiation.
Environmental and biological risk factors
Graft versus host disease can happen after a donor stem cell or bone marrow transplant. Some risks are carried inside the body, others come from the world around us. When people ask about risk factors for graft versus host disease after stem cell transplant, the biggest ones are immune differences between donor and recipient, how the transplant cells are collected, and how much inflammation is present around the time of transplant.
Graft versus host disease only develops when donor immune cells are part of the transplant. It does not happen when people receive their own previously collected cells.
The more the donor immune system differs from the recipient, the more likely it is to react against the body. Larger immune differences are one of the strongest biological risk factors for graft versus host disease. This is why less closely compatible donor transplants often carry more risk.
Older recipients and older donors have a higher risk, especially for chronic graft versus host disease. Age-related changes in the immune system may make immune reactions harder to control.
A female donor for a male recipient can raise the risk of graft versus host disease. The risk is higher if the donor has been pregnant before, because prior immune exposure can make donor cells more reactive.
Genetic risk factors
For many people, the inherited risks for graft versus host disease come down to how different the donor's immune markers are from the recipient's. The most important genetic risk factors for graft versus host disease involve HLA tissue-type genes, but other inherited protein differences can matter too. It’s usually a combination of influences rather than one clear cause. A close match lowers risk, although it cannot remove it completely.
HLA mismatch: The strongest genetic risk for graft versus host disease is a mismatch in HLA tissue-type genes between donor and recipient. When these inherited markers differ, donor immune cells are more likely to treat the body as foreign and attack it.
Half-matched donor: A donor who shares only half of the HLA pattern usually brings a higher GVHD risk than a closely matched donor. This is because there are more inherited differences for the immune system to react to.
Minor antigens: Even with a good HLA match, smaller inherited differences in other body proteins can still trigger GVHD. Donor immune cells may recognize these proteins as unfamiliar and start an immune attack.
Sex mismatch: GVHD risk can be higher when a female donor gives stem cells to a male recipient. One reason is that donor immune cells may react to proteins linked to the Y chromosome, which are found only in males.
Unrelated donor: Even when the main HLA markers match well, GVHD is often more likely with an unrelated donor than with a matched sibling. That is partly because unrelated people usually differ in more small inherited immune markers outside the main matching genes.
Lifestyle risk factors
Graft versus host disease is a transplant-related immune condition, so daily habits do not usually cause it to start. However, how lifestyle affects graft versus host disease can matter for symptom control, recovery, and the risk of complications while the immune system is already under strain. The most important factors are habits that increase inflammation, weaken tissue healing, raise infection risk, or make it harder to tolerate treatment.
Smoking can worsen lung irritation, slow tissue repair, and increase infection risk in people with graft versus host disease. It may also make mouth, skin, and breathing symptoms harder to control during treatment.
Heavy alcohol use can irritate the liver and digestive tract, which is especially important when graft versus host disease affects those organs. It can also worsen dehydration, poor sleep, and medication side effects.
Poor intake, highly processed foods, and low protein can make weight loss, weakness, and slow healing more likely during graft versus host disease. A well-tolerated, nutrient-dense diet may better support the gut, immune recovery, and overall strength.
Unsafe food handling or high-risk foods can raise the chance of foodborne infection when graft versus host disease or its treatment has weakened immune defenses. This is particularly important if the gut is involved or immunosuppressive medicines are being used.
Risk prevention
For many, graft versus host disease is something doctors try to prevent around the time of a donor stem cell or bone marrow transplant. It cannot always be fully prevented, because it depends on how the donor cells react inside the body, but careful planning can lower the risk and help catch problems early. Prevention can mean both medical steps, like medicines that calm the immune system, and lifestyle steps, like infection prevention and close follow-up.
Careful donor matching is one of the main ways to lower the risk of graft versus host disease. The closer the donor and recipient are matched, the less likely the new immune cells are to attack healthy tissues.
Most people receive medicines before and after transplant to reduce immune system overreaction. Taking these exactly as prescribed can lower the chance of early symptoms of graft versus host disease and may also reduce severity if it develops.
In some situations, the type of donor cells used can affect risk. Your transplant team may choose a source, such as cord blood or specially prepared donor cells, that better fits your health needs and lowers the chance of graft versus host disease.
Frequent blood tests, skin checks, and review of new symptoms help doctors spot warning signs early. Prevention works best when combined with regular check-ups.
Can you prevent Graft versus host disease?
You cannot fully prevent graft-versus-host disease, but the risk can often be lowered. Doctors try to prevent it by choosing the closest possible donor match and giving medicines that calm the donor immune cells before and after a bone marrow or stem cell transplant. Even with these steps, some people still develop it, so close follow-up after transplant is very important.
Transmission
Graft versus host disease is not contagious, so it does not spread through coughing, kissing, sex, food, or everyday contact. Many people with graft versus host disease develop it after an allogeneic stem cell or bone marrow transplant, when immune cells from the donor enter the body and start attacking the recipient's tissues because they recognize them as different.
In rare cases, graft versus host disease can also happen after a blood transfusion if donor white blood cells are not removed or inactivated. So if you are wondering whether graft versus host disease is infectious, the answer is no: the risk comes from donor immune cells transferred during certain medical treatments, not from catching it from someone else.
When to test your genes
For graft-versus-host disease, genetic testing is usually done before a stem cell transplant, not later for early detection. The key test is HLA typing, which checks how closely donor and recipient immune markers match and helps guide donor choice and some aspects of transplant planning.
Diagnosis
Graft versus host disease is usually diagnosed after a stem cell or bone marrow transplant when new symptoms appear, such as a rash, diarrhea, dry eyes, mouth sores, jaundice, or unusual tiredness. Doctors usually begin by looking at when symptoms started, which organs seem affected, and whether the pattern fits acute or chronic disease. It’s natural to worry when symptoms don’t have a clear explanation.
The diagnosis of graft versus host disease starts with a careful review of symptoms and when they began after transplant. Timing matters because symptoms in the first weeks may suggest acute disease, while later changes can point to chronic disease.
A physical exam looks for common signs such as skin rash, skin tightening, mouth sores, dry eyes, swelling, or jaundice. These findings help show which parts of the body may be involved and how severe the problem might be.
Blood tests can check liver function, blood cell counts, inflammation, and signs of infection or medication side effects. This helps doctors separate graft versus host disease from other common problems after transplant.
Stool tests may be used when there is diarrhea, stomach pain, or bleeding to look for infection and other causes. Urine tests can also help assess dehydration, kidney strain, or related complications.
How is Graft versus host disease diagnosed?
Doctors usually diagnose graft-versus-host disease by looking at when symptoms start after a donor stem cell or bone marrow transplant, which parts of the body are affected, and what they find on the exam and blood tests. They also make sure the symptoms are not being caused by something else, such as an infection, a medicine side effect, or another transplant-related problem. If needed, they may confirm the diagnosis with a small tissue sample from the skin, gut, or liver, and sometimes with a camera test to look inside the digestive tract.
Stages of Graft versus host disease
Graft versus host disease does not have defined progression stages. This is because it is usually described by when it happens and which organs it affects, rather than by a steady step-by-step worsening over time. Doctors usually start with a conversation about symptoms such as rash, diarrhea, dry eyes, mouth sores, or shortness of breath, along with an exam and blood tests to look for early symptoms of graft versus host disease and other possible causes. Monitoring may also include skin, liver, gut, or lung tests, and sometimes a small tissue sample called a biopsy to confirm the diagnosis.
Outlook and prognosis
Outlook in graft versus host disease varies widely depending on whether it is acute or chronic, which organs are involved, and how quickly it responds to treatment. Mild cases limited to the skin or mouth may improve with corticosteroids and other immune-modifying therapies, while severe disease affecting the gut, liver, or lungs can be prolonged and disabling. Acute severe graft versus host disease is associated with a higher risk of life-threatening infections, organ failure, and treatment-related complications, and chronic disease can lead to long-term problems such as scarring, reduced mobility, eye and mouth dryness, and poor quality of life. Survival has improved with better donor matching, preventive regimens, and newer treatments, but mortality remains significant in refractory or advanced cases. Overall prognosis is best when the disease is recognized early, controlled promptly, and managed by an experienced transplant team.
Long-term effects
For many people, graft versus host disease can leave lasting changes even after the most intense treatment phase has passed. Long-term effects vary widely, depending on which organs are involved and how active the disease remains. Thinking about the long-term effects helps explain why some people need years of follow-up, while others recover with fewer ongoing problems.
Graft versus host disease can cause long-lasting dry, tight, itchy, or darker skin, and some people develop scarring that limits movement. In more severe cases, the skin can feel stiff enough to make daily tasks like dressing or reaching overhead harder.
Ongoing dryness in the mouth and eyes is common and can make eating, speaking, reading, or wearing contact lenses uncomfortable. Some may also have mouth sores, taste changes, or trouble swallowing dry foods.
Some people develop lasting inflammation and scarring in the airways, which can lead to cough, wheezing, or shortness of breath with walking or climbing stairs. These breathing changes may appear months after transplant, even when earlier symptoms of graft versus host disease seemed to be improving.
Long-term liver involvement can cause abnormal blood tests, jaundice, itching, or ongoing fatigue. When liver damage is significant, doctors may need to monitor for scarring and reduced liver function over time.
How is it to live with Graft versus host disease?
Living with graft-versus-host disease can feel unpredictable because symptoms often come in waves and may affect the skin, mouth, eyes, lungs, liver, gut, or joints, so daily routines sometimes have to bend around fatigue, pain, dry eyes or mouth, stomach trouble, frequent appointments, and careful infection precautions. For many people, this can mean pacing activities, adjusting work or school, being more selective about crowds and travel, and staying closely connected to a transplant team while medicines are adjusted over time. The people around you are often affected too, because family and friends may help with transportation, meals, medication schedules, and emotional support, and they may need to be extra mindful about avoiding infections when visiting. Even so, many living with graft-versus-host disease gradually find a new rhythm, and with good medical follow-up and practical support, day-to-day life often becomes more manageable.
Treatment and drugs
Graft versus host disease is usually treated by calming the donated immune cells that are attacking the body, while also protecting organs such as the skin, gut, liver, eyes, or lungs. The main treatments are medicines that lower immune activity, most often steroids at first, and many living with graft versus host disease may also need other immune-targeting drugs if symptoms are moderate, severe, long-lasting, or come back. Doctors sometimes recommend a combination of lifestyle changes and drugs. Supportive care is also important for day-to-day comfort and safety, including pain relief, skin and eye care, treatment for diarrhea or mouth sores, physical therapy, and careful prevention or treatment of infections. Finding the right therapy can take some time, especially because treatment depends on whether graft versus host disease is acute or chronic, how severe it is, and which parts of the body are affected.
Can you cure Graft versus host disease?
There is no guaranteed cure for graft-versus-host disease, but treatment can often bring it under control, and some cases do go away completely. Medicines that calm the donor cells causing the attack, along with treatment for affected areas like the skin, gut, eyes, or liver, can ease symptoms and help prevent more damage. For many living with chronic graft-versus-host disease, it can become a long-term condition that needs ongoing care.
Non-drug treatment
Day-to-day care can make a real difference for people living with graft versus host disease, especially when symptoms affect the skin, eyes, mouth, lungs, joints, or digestion. Beyond prescriptions, supportive therapies can reduce discomfort, protect body tissues, and help you stay active and independent. The best plan depends on which parts of the body graft versus host disease is affecting and whether symptoms are short-term or ongoing. Often, care works best when several approaches are combined.
Gentle skin care, thick moisturizers, and careful sun protection can ease dryness, itching, and tightness in people with graft versus host disease. If skin becomes stiff or scar-like, regular stretching and specialist wound care may help protect movement and comfort.
Dry, gritty, burning eyes are common, and simple measures like warm compresses, eyelid hygiene, moisture chamber glasses, and punctal plugs can help keep the eye surface protected. For many living with graft versus host disease, practical eye care for graft versus host disease can make reading, screen time, and going outdoors feel more manageable.
Frequent sips of water, saliva substitutes, gentle oral rinses, and regular dental care can help with a dry, sore mouth and trouble eating. Soft toothbrushes and avoiding irritating foods, such as very spicy or acidic meals, may also lower discomfort.
When eating is painful or the gut is affected, a dietitian can help adjust food texture, meal size, and calorie intake so it is easier to keep up strength. Some may find that small, frequent meals are easier than large ones, especially during flares.
Your genes may have an impact on how drugs work for you
For people living with graft-versus-host disease, the same medicine can work a little differently from one person to another because inherited differences can change how fast the body breaks down certain immune-suppressing drugs, which can affect both benefit and side effects. In daily life, this may mean one person needs a higher or lower dose to get the right effect, while another may be more likely to have problems such as kidney strain, shakiness, or trouble fighting infections. Genetic testing is not the main guide for most graft-versus-host disease treatment, but for some transplant medicines it can sometimes help doctors choose a safer starting dose and then fine-tune it with blood tests and close follow-up.
Pharmacological treatments
Graft versus host disease is often treated with medicines that calm an overactive immune response, because the donor cells are attacking the body’s own tissues. The choice depends on whether the problem is acute or chronic, which organs are affected, and how severe symptoms are. Not everyone responds to the same medication in the same way. For many living with graft versus host disease, treatment may need to be adjusted over time to balance symptom control with side effects and infection risk.
Prednisone and methylprednisolone are usually the first-line treatment for graft versus host disease because they can quickly reduce inflammation. They are often used for both acute and chronic graft versus host disease, but long-term use can raise the risk of infections, high blood sugar, weak bones, and mood changes.
Tacrolimus and cyclosporine are immune-suppressing drugs often used with steroids or when steroid doses need to be lowered. They can help protect the skin, gut, liver, or other organs, but they require blood tests because they may affect the kidneys, blood pressure, and drug levels.
Ruxolitinib is a targeted medicine often used when steroids have not worked well enough, especially in steroid-refractory acute graft versus host disease and some cases of chronic disease. Many people find relief when the right medicine starts easing rash, diarrhea, or liver inflammation, although blood counts can drop and infections can become more likely.
Belumosudil is used for chronic graft versus host disease after at least one earlier treatment has not helped enough. It may improve tight skin, mouth discomfort, joint stiffness, or breathing symptoms over time, though liver tests and other side effects still need monitoring.
Genetic influences
In graft versus host disease, genetics matter most in how closely a donor’s immune markers match the recipient’s. After a stem cell or bone marrow transplant, donor immune cells may react against the recipient’s skin, gut, liver, or other tissues if they see them as different. The main genes involved are the HLA genes, which help the immune system tell what belongs in the body and what does not, and a closer HLA match usually lowers the genetic risk of graft versus host disease. Other immune-related gene differences outside HLA can also affect who gets graft versus host disease and how severe it becomes. Having a genetic risk is not the same as having the disease itself, because even a very good match cannot remove the risk completely, while some people with less-than-perfect matches do well. This is why transplant teams do careful donor-recipient genetic matching before transplant and use that information to plan prevention and follow-up.
Is Graft versus host disease genetic?
Genetics matter a lot in graft versus host disease, especially how closely donor and recipient tissue types match. Other gene differences in immune signaling can also affect risk, severity, and how someone responds to treatment.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are common in the general population and are a normal part of being human. Most of these variants do not directly affect health and are simply part of natural human diversity. For many genes, having a variant linked to a condition suggests a possible association rather than a definite diagnosis, especially when several genes and environmental factors play a role. In some situations, though, a single well-characterized variant in a particular gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
After a stem cell transplant, treatment for graft-versus-host disease often has to be tailored closely, because the same drug dose can work very differently from one person to another. The donor’s and recipient’s immune-system genes, especially the tissue-matching markers used before transplant, help shape GVHD risk, which can affect the medicines doctors choose to prevent it and how closely they monitor treatment. Genes can influence how quickly you process medicine, so drugs such as tacrolimus or cyclosporine may build up too much in some people and wear off too quickly in others. For many living with graft-versus-host disease, that can mean the difference between drug levels that are too low to control inflammation and levels high enough to raise the chance of kidney problems, tremor, or infection. Some centers use genetic test results, along with blood drug levels and your overall health, to guide starting doses or dose changes, especially when early symptoms of graft-versus-host disease are hard to control. Even so, genetics does not replace regular follow-up, because age, liver and kidney function, other medicines, and the transplant itself also strongly affect how well treatment works.
Interactions with other conditions
People living with graft versus host disease can be more vulnerable when another illness is present, especially infections, because both the disease and the medicines used to control it can weaken immune defenses. Day-to-day, it can feel like one health issue amplifies the other, such as when a mild chest infection becomes harder to clear or when stomach inflammation from another condition makes gut symptoms worse. Graft versus host disease can also affect the skin, liver, lungs, and digestive tract, so it may overlap with problems like chronic liver disease, lung scarring, or bowel inflammation and make symptoms harder to sort out. In some cases, it can look similar to autoimmune illnesses because the immune system attacks healthy tissues, although the cause is different. People with graft versus host disease may also have a tougher recovery if they develop diabetes, kidney disease, or poor nutrition, since these can complicate healing and treatment choices. If you are wondering how graft versus host disease affects other health problems, it helps to review all symptoms and medicines together with your care team, because interactions can vary a lot from one person to the next.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Graft versus host disease?
After a stem cell transplant, problems that can look like graft versus host disease include infections, side effects from medicines, and irritation left behind by chemotherapy or radiation. These can cause a rash, diarrhea, belly pain, dry eyes or mouth, or signs of liver trouble on blood tests, much like graft versus host disease. Depending on which body part is affected, doctors may also consider other common causes such as eczema or other skin rashes, hepatitis, or other types of bowel inflammation.
History
People living with graft versus host disease are dealing with a problem that came into view as doctors began using bone marrow and stem cell transplants more often. Early on, transplant teams saw that some people recovered well, while others developed rashes, diarrhea, liver problems, or ongoing dry eyes and mouth weeks to months later. At first, these complications were understood mainly through what doctors could observe at the bedside, especially after donor cells had begun to grow in the body.
As medical science evolved, it became clearer that graft versus host disease was linked to the immune cells in the donated transplant reacting against the recipient’s tissues. This understanding grew during the mid-20th century, especially as animal studies and early human transplant experience helped explain why the condition happened. Over time, doctors also recognized that graft versus host disease could appear in different forms, including an earlier, more sudden illness and a later, longer-lasting pattern that can affect daily life in a more gradual way.
These historical steps led to major changes in care. Doctors improved donor matching, refined transplant methods, and developed medicines to lower the risk of graft versus host disease or treat it when it appeared. Researchers later identified a genetic basis for why donor and recipient immune systems may respond differently, but the biggest shift for patients was practical: transplant care became more careful, more personalized, and much better at watching for early symptoms of graft versus host disease.
Today, graft versus host disease is still a serious complication, but it is better understood than it once was. Many living with graft versus host disease now benefit from earlier diagnosis, closer follow-up, and treatments aimed at controlling inflammation while protecting the transplant. Knowing this history helps explain why transplant care can feel so closely monitored after the procedure: those check-ins are built on decades of learning from earlier patients and steadily improving care.